The DBGen rod-cone dystrophy panel includes a genetic study of 47 genes known to cause the disease.
Rod-cone dystrophy exhibits autosomal dominant, autosomal recessive and X-linked pattern of inheritance. It is characterized by a dysfunction of the cones that, in a high percentage of cases, precedes the degeneration of the rods. It initially causes a drop in visual acuity, defects in color vision, photophobia and loss of central vision. Its prevalence is between 1:30,000 and 1:40,000. Although the number of genes known is high, cone-rod dystrophy is the least successfully diagnosed of all retinal dystrophies.
The panel includes the genes most often responsible for the following retinal disorders:
ABCA4, ADAM9, ADAMTS18, AIPL1, BEST1, C21orf2, C8orf37, CABP4, CACNA1F, CACNA2D4, CDHR1, CEP78, CERKL, CLN3, CNGA3, CNGB3, CNNM4, CRB1, CRX, CYP4V2, DRAM2, GNAT2, GUCA1A, GUCY2D, KCNV2, MERTK, OPN1LW, OPN1MW, PDE6C, PDE6H, PITPNM3, POC1B, PROM1, PRPH2, RAB28, RAX2, RDH5, RGS9, RGS9BP, RIMS1, RLBP1, RPGR, RPGRIP1, SEMA4A, SEMA6B, TTLL5, UNC119
Non-coding regions included: ABCA4 all introns, RPGRIP1 promotor
This test is recommended when the clinical diagnosis indicates one of the pathologies previously listed and when the clinical condition is clearly defined.
This panel is part of the Complete Panel of Retinal Dystrophies and other eye diseases and offers a very high diagnostic yield as it includes a high number of causative genes and because the method used allows identifying some structural genomic alterations difficult to characterize with other test types.
From €825. Please contact us to know the options that best suit your needs.
A detailed genetic report that includes the genetic variants identified and genetic counseling will be provided. Supporting information will be exhaustive based on bibliographical studies and database analyses and, especially, on our 25 years of experience researching the genetics of hereditary eye diseases.
The test will be performed once payment is made and the signed informed consent and the sample are received. The report will be delivered 12 to 14 weeks after the above conditions are satisfied.
The diagnostic strategy relies on the automated sequencing of DNA on Illumina HiSeq 2000 sequencers that are specially designed for this kind of high-performance analysis. Our panels have been designed to prioritize the genomic regions associated with the hereditary eye diseases indicated in this text.
The likely pathogenic nucleotide variants are verified using Sanger sequencing. We check that their frequency in the control population is below 1% and that they meet the pathogenicity predictions as per established bioinformatics algorithms (SIFT, LRT, MutationTaster, PolyPhen2, CADD and NetGene2).